Articles tagged with Drug Therapy
Researchers have developed a novel gene therapy approach that targets and breaks down faulty ribonucleic acids in the KCNA2 gene, which is associated with recurring seizures. The therapy has shown promise in reducing excessive neuron activity linked to epilepsy.
A new technique called Clonal competition assays helps understand the evolutionary advantages of multiple myeloma cells over available treatments. It allows researchers to see how each population of cells in the same myeloma reacts to treatments, getting closer to understanding heterogeneity and resistance.
A non-invasive blood test measuring circulating tumor cells can predict treatment response, disease progression, and overall survival in men with metastatic prostate cancer. Patients with more CTCs had shorter median survival lengths and a greater risk of death.
The University of Liverpool will lead a £60m national research hub to develop and manufacture new long-acting therapeutics, positioning the UK as a global leader in this field. The Hub for Advanced Long-acting Therapeutics (HALo) aims to create new proof-of-concept medicine candidates for diseases like high blood pressure and asthma.
A new CAR-T cell therapy targeting CD7 on leukaemia cells has shown promising results in treating T-ALL patients who have exhausted all standard treatment options. The therapy achieved complete remission in 16 out of 17 patients, with some remaining in remission for over five years.
A recent study published in Liver Cancer found that patients with diabetes mellitus and comorbid obesity are at a higher risk of liver cancer recurrence after resection. The risk is significantly higher for those with comorbid obesity, increasing by approximately 3.8 times over five years postoperatively.
A study suggests that online insomnia treatment, SHUTi, can provide meaningful relief for caregivers struggling with sleep difficulties. The program showed promising results in improving sleep quality and reducing stress among high-intensity caregivers, those shouldering the greatest responsibilities in caring for their loved ones.
Scientists at RIKEN CPR created a method to change albumin's molecular ID card, allowing for targeted treatments against diseases like cancer. The new technology can transport proteins out of the body, mimicking drug delivery and removal.
Researchers at UConn have discovered a novel miRNA-141-3p inhibitor that successfully reduces stroke damage and extinguishes inflammatory fires in the brain. The treatment has shown swift restoration of motor function and memory in mouse models, offering new hope for patients affected by strokes.
Two UCF cancer researchers, Alicja Copik and Debbie Altomare, have received $100,000 grants from the Florida Breast Cancer Foundation to develop new treatments for breast cancer. They focus on enhancing natural killer cells to fight cancer and harnessing the body's immune system to create new therapies.
Researchers at Texas Biomedical Institute have developed a TB therapy that does not interfere with combined antiretroviral therapy (cART) in patients with HIV. The host-directed therapy blocks an immune system protein and has shown improved control of TB when used with antibiotics.
A new trial suggests that adding immunotherapy to chemoradiation can extend survival in patients with limited-stage small cell lung cancer. However, the findings also indicate that delivering the treatments at different times yields varying results, with concurrent treatment not offering improved survival benefits.
A clinical trial found that mavacamten, a cardiac myosin inhibitor, reduced biomarkers of cardiac wall stress and injury in patients with heart failure. The treatment showed no significant reduction in left ventricular ejection fraction.
A phase II clinical trial found that radiopharmaceuticals, specifically 177Lu-Dotatate, can extend progression-free survival for patients with refractory meningioma by nearly 80% after six months. The therapy offers a safe and effective treatment option for those with aggressive tumor growth.
Long-term treatment with the nonsteroidal mineralocorticoid receptor antagonist finerenone is estimated to extend event-free survival by up to 3 years among people with heart failure. The FINEARTS-HF randomized clinical trial found this benefit in patients with mildly reduced or preserved ejection fraction.
Researchers discovered that activating the pentose phosphate pathway makes antitumor CD8 T cells more likely to stay in an immature state, leading to better results in animal models and human organoids. This metabolic reprogramming strategy may enhance checkpoint inhibitor therapy by boosting a long-term supply of active cytotoxic T ce...
A new study suggests the hormone hepcidin may trigger psoriasis by causing iron overload in the skin. This excess iron amplifies the damaging effects of UV sunlight, leading to hyperproliferative chronic diseases like psoriasis. A potential treatment targeting hepcidin could improve treatment options for millions.
Scientists at Anglia Ruskin University are collaborating with Medannex to accelerate treatment for bone cancer in children, focusing on paediatric osteosarcoma. The first-in-class therapy MDX-124 has shown promising results in preclinical tests and is being evaluated in a clinical study.
Treatment-emergent nirmatrelvir resistance mutations were commonly detected in immunosuppressed individuals, but at low frequencies and transient nature. The study suggests a low risk for the spread of nirmatrelvir resistance in the community with current variants and drug usage patterns.
The CRISPR-Cas13 system enables temporary gene expression manipulation without permanent genomic changes, holding promise for treating diseases caused by RNA defects. It has been applied to correct mutations linked to Duchenne muscular dystrophy and can be used to alter splicing events, making it a powerful tool in personalized medicine.
Researchers identified the external globus pallidus as responsible for impaired decision-making in mice with Parkinson's disease treated with pramipexole. Hyperactivation of this region was linked to poor risk-taking behavior and reduced effectiveness of treatments.
A new study reveals how psilocybin alters brain connectivity to alleviate symptoms of body dysmorphic disorder, potentially aiding treatment. Psilocybin strengthens neural connections between executive functions and emotionally salient stimuli, leading to improved BDD symptoms.
Researchers at St. Jude Children's Research Hospital found that patients with ETV6::RUNX1 and high-hyperdiploid B-ALL can achieve positive outcomes with low-intensity chemotherapy, tailoring treatment based on genetic subtypes and early treatment response. This approach reduces side effects and improves event-free survival rates.
Researchers discovered that certain bacteria display communal behaviors protecting sensitive species from drugs, allowing them to grow normally in a community. The study found that high drug concentrations cause microbiome communities to collapse and cross-protection strategies are replaced by cross-sensitisation.
A new study found that up to 10 million people in the US could qualify for Medicare-covered semaglutide injections, depending on their level of cardiovascular risk. Those with higher risk scores would be eligible for full or partial coverage, potentially expanding access to this life-saving medication.
A 6-month study found that psilocybin offered similar improvements to SSRI escitalopram in depressive symptoms, but with greater social functioning and psychological connectedness. Psilocybin may offer an alternative for those not responding to SSRIs, but its benefits are still being studied.
Researchers at ETH Zurich have found an antidepressant, vortioxetine, effective against glioblastomas, a particularly aggressive brain tumor with no cure. The drug's ability to cross the blood-brain barrier and trigger a signalling cascade makes it promising for treating this deadly tumour.
A novel drug molecule has been found to reactivate a crucial protein called parkin, which plays a key role in maintaining healthy brain cells. The study's findings lay the foundation for the design of personalized treatments for younger patients with specific mutations, offering new hope for a cure for Parkinson's disease.
UTHealth Houston researchers are exploring new pathways to treat Alzheimer's disease through multiple projects funded by the Texas Alzheimer's Research and Care Consortium. Studies aim to investigate ACSL4 gene, delirium's impact on disease progression, biological aging, and noninvasive diagnosis methods.
A recent study found significant therapeutic inertia in the treatment of women with multiple sclerosis (MS), leading to delayed or reduced use of disease-modifying treatments. The research highlights gender disparities that could impact long-term health outcomes for women of childbearing age, particularly due to concerns about pregnanc...
Researchers found that low extracellular sodium concentrations decrease specific mRNA expression and nitric oxide production in microglia, potentially contributing to hyponatremia-induced neuronal dysfunctions. Microglial activation can lead to inflammation and regulate neurotransmission.
Researchers developed a label-free biological sensing method that can detect substances at the zeptomolar level, significantly improving drug testing and research capabilities. This advancement has the potential to lead to portable sensors for environmental toxins, food quality monitoring, and cancer screening.
Prescription volumes for stimulant and antidepressant medications rose, while opioid volumes decreased between 2019 and 2022. Telehealth prescriptions climbed across medications, with a notable increase in opioids.
Researchers at NYU Abu Dhabi have developed nanoscale covalent organic frameworks (nCOFs) modified with peptides to treat triple-negative breast cancer. The COFs selectively release drug cargo within the acidic environment of tumors, improving treatment effectiveness and minimizing side effects.
A retrospective cohort study of 3,389 patients with obesity found that semaglutide and liraglutide were associated with significant weight reduction at 1 year. The study suggests that persistent medication coverage, dosage, treatment indication, and patient sex are important factors in determining weight loss outcomes.
CAR-T cell therapy, a regenerative immunotherapy, has shown promise in treating blood cancers but struggles with T-cell exhaustion. Researchers have discovered that overproduction of the IL-4 protein causes this exhaustion and used CRISPR gene-editing technology to remove it, improving CAR-T cell therapy outcomes.
Researchers at NTU Singapore and Oxford have identified a new process called nucleophagy that helps cells remove harmful DNA-protein lesions, promoting genetic material stability and cell survival. This discovery may improve cancer treatment outcomes for patients with colorectal cancer.
A UBCO study found that patients face barriers when discussing psychedelics with physicians due to stigma and perceived lack of knowledge. The study analyzed data from 800 adults who use psychedelics, revealing that nearly 60% felt less satisfied with communication about psychedelics compared to previous conversations.
A clinical trial found that sulthiame, a drug used for epilepsy, reduces pauses in breathing and improves oxygen levels in patients with obstructive sleep apnea. The treatment also alleviates daytime fatigue, suggesting it could be an effective alternative to existing mechanical treatments.
A four-year grant will help researchers find new clues to the interplay between Down syndrome and myeloid leukemia, focusing on enhancing antileukemic activity of chemotherapy drug cytarabine. The goal is to identify a novel treatment strategy to improve patient outcomes and prevent relapses in ML-DS patients.
The FDA Letter of Support recognizes the potential of αSyn-SAA to accelerate clinical trial design in Parkinson's and related disorders. This biomarker can objectively detect early biology related to these diseases, enabling research toward tailored therapies and potentially delaying or preventing disease onset.
A new framework from a global team of scientists aims to overcome translational hurdles in nanomedicine development. The DELIVER guidelines provide early-stage recommendations for maximizing clinical translation and enabling the successful development of new nanomedicine treatments.
Researchers at Johns Hopkins Medicine found that age-related changes in male fibroblasts contribute to more aggressive and treatment-resistant melanomas. The study discovered that male fibroblasts accumulate reactive oxygen species and produce higher levels of BMP2, leading to increased DNA damage and resistance to targeted therapies.
Researchers developed a gene therapy that restored useful vision to most patients with Leber congenital amaurosis type I, a rare inherited blindness. The treatment showed a 10,000-fold improvement in light sensitivity and improved navigation abilities in patients who received the highest dose.
Researchers discovered faulty immune processes responsible for lingering lung issues after COVID-19, which can be disrupted by existing drugs. The study also identified molecules responsible for the issue and potential therapeutic options for patients with ongoing lung damage.
A literature review examines key cell-cell interactions driving pulmonary fibrosis, revealing complex interplay between diverse lung cell types and intricate processes. The study highlights potential ligands involved in PF, including tumor necrosis factor, interleukin 1β, and ADAM17, and suggests targeting CCIs for novel therapies.
Researchers investigated peptide clumping behavior using molecular dynamics simulations and AI techniques. They discovered that aromatic amino acids enhance aggregation, while hydrophilic ones inhibit it, offering insights into peptide structure and function.
A clinical trial led by UC San Francisco aims to develop new therapies for progressive supranuclear palsy, with a focus on reducing time to find effective treatments and increasing diverse participant enrollment. The five-year grant could lead to the first effective drugs for this incurable neurodegenerative disorder.
Researchers at Flinders University and University of South Australia have discovered a potential breakthrough in treating the most aggressive forms of prostate cancer using CDKI-73, a novel drug inhibitor. The study found that CDKI-73 effectively blocks the growth of prostate cancer cells while sparing normal cells.
A low-dose triple-pill protocol demonstrated improved blood pressure lowering and control, with good tolerability, compared to standard-care protocols for Black African adults with uncontrolled hypertension. The study results have significant implications for hypertension treatment in Nigeria.
Researchers have developed a new method to increase speed and success rates in drug discovery by combining data from the Library of Integrated Network-based Cellular Signatures with targeted docking simulations. This approach can accelerate the drug research process, identifying potentially effective compounds more efficiently.
Researchers have shown that repeated administration of lipid nanoparticle-encapsulated mRNA therapy significantly extended survival and reduced serum leucine levels in a mouse model of maple syrup urine disease. The treatment approach may represent a potential long-term universal treatment for MSUD.
The Northwestern University Clinical and Translational Sciences Institute has received $55 million in NIH funding to accelerate the development, evaluation, and implementation of improved healthcare interventions. The grant will support the development of effective health interventions for more patients more quickly, with a focus on ad...
Researchers at the University of Hawaii have developed a new gene editing technology that can efficiently deliver healthy genes to the body. This method addresses limitations of current methods and has shown success rates of up to 96%, potentially leading to faster and more affordable treatments for various genetic diseases.
Scientists at Van Andel Institute and Icahn School of Medicine have developed a potent anti-cancer compound that inhibits cancer cell growth in MLL-rearranged leukemia. MS-41 effectively targets and degrades ENL, a protein essential to the progression of leukemia cells.
Recent years have seen therapeutic advances in kidney cancer due to deeper understanding of the disease's biology, with improved treatments and early detection contributing to decreased deaths. Cigarette smoking and being overweight remain major risk factors for kidney cancer.
A multi-university research team led by University of Virginia engineering professor Gustavo K. Rohde has developed a system that can accurately spot genetic markers of autism in brain images. The system uses generative computer modeling technique called transport-based morphometry, which reveals brain structure patterns that predict v...
A five-year study led by Tulane University is investigating a new medication to treat trichomoniasis. The research compares secnidazole with metronidazole, finding that one-dose treatment could offer better options for the infection, which affects 156 million people annually.
TCT 2024 features groundbreaking research on minimally invasive techniques, pharmaceuticals, technologies, and devices to treat or prevent cardiovascular disease. The event showcases the latest advancements in interventional cardiology and offers a platform for clinicians to learn about new interventions and strategies.
Researchers at Åbo Akademi University have discovered a crucial protein, TLNRD1, that helps maintain blood vessel stability in the brain. The study highlights the potential for targeted molecular therapies to improve patient outcomes in CCM disease.